Impairment of prostate cancer cell growth by a selective and reversible LSD1 inhibitor
International Journal of Cancer, 04/25/2012
Willmann D et al. – Namoline is a novel promising starting compound for the development of therapeutics to treat androgen–dependent prostate cancer.



